Trial Profile
Comparative cardiovascular (CV) risk of SGLT2 inhibitors (canagliflozin and empagliflozin) and liraglutide in patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2018
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Empagliflozin (Primary) ; Liraglutide (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- 20 Jul 2018 New trial record